Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
SSE:688621.SS
54.23 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,078.474 | 932.12 | 676.606 | 493.646 | 347.356 | 233.526 | 134.796 | 36.05 |
| Cost of Revenue
| 537.334 | 403.771 | 301.148 | 229.965 | 175.023 | 126.356 | 77.662 | 21.731 |
| Gross Profit
| 541.14 | 528.349 | 375.458 | 263.681 | 172.333 | 107.17 | 57.134 | 14.319 |
| Gross Profit Ratio
| 0.502 | 0.567 | 0.555 | 0.534 | 0.496 | 0.459 | 0.424 | 0.397 |
| Reseach & Development Expenses
| 171.944 | 123.684 | 89.686 | 47.577 | 34.192 | 19.066 | 8.461 | 2.805 |
| General & Administrative Expenses
| 17.543 | 18.546 | 15.53 | 11.351 | 9.741 | 5.061 | 3.126 | 0.907 |
| Selling & Marketing Expenses
| 25.622 | 26.65 | 20.273 | 17.031 | 8.71 | 5.999 | 3.253 | 1.194 |
| SG&A
| 43.165 | 44.061 | 35.803 | 28.382 | 18.451 | 11.059 | 6.379 | 2.101 |
| Other Expenses
| 148.342 | 166.443 | 60.11 | 52.909 | 33.684 | 23.995 | -0.35 | -0.03 |
| Operating Expenses
| 363.451 | 334.188 | 185.599 | 128.868 | 86.328 | 54.12 | 28.723 | 12.056 |
| Operating Income
| 177.689 | 194.161 | 169.274 | 122.591 | 82.784 | 55.042 | 23.631 | 1.153 |
| Operating Income Ratio
| 0.165 | 0.208 | 0.25 | 0.248 | 0.238 | 0.236 | 0.175 | 0.032 |
| Total Other Income Expenses Net
| -1.702 | -0.765 | -0.136 | -0.49 | -0.501 | -0.586 | -0.35 | -0.03 |
| Income Before Tax
| 175.987 | 193.397 | 169.138 | 122.101 | 82.284 | 54.455 | 23.281 | 1.123 |
| Income Before Tax Ratio
| 0.163 | 0.207 | 0.25 | 0.247 | 0.237 | 0.233 | 0.173 | 0.031 |
| Income Tax Expense
| 6.974 | 10.502 | 11.098 | 13.309 | 8.121 | 6.522 | 3.12 | 0.001 |
| Net Income
| 177.409 | 184.757 | 156.473 | 105.662 | 72.465 | 47.401 | 20.718 | 1.98 |
| Net Income Ratio
| 0.165 | 0.198 | 0.231 | 0.214 | 0.209 | 0.203 | 0.154 | 0.055 |
| EPS
| 1.58 | 1.65 | 1.39 | 0.94 | 0.65 | 0.42 | 0.25 | 0.021 |
| EPS Diluted
| 1.58 | 1.65 | 1.39 | 0.94 | 0.65 | 0.42 | 0.25 | 0.021 |
| EBITDA
| 242.117 | 250.504 | 231.86 | 159.097 | 93.776 | 65.759 | 30.684 | 4.221 |
| EBITDA Ratio
| 0.224 | 0.269 | 0.343 | 0.322 | 0.27 | 0.282 | 0.228 | 0.117 |